{"id":6844,"date":"2026-07-29T11:12:49","date_gmt":"2026-07-29T11:12:49","guid":{"rendered":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/?p=6844"},"modified":"2026-07-29T11:37:39","modified_gmt":"2026-07-29T11:37:39","slug":"juvenile-dermatomyositis","status":"publish","type":"post","link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/juvenile-dermatomyositis\/","title":{"rendered":"Juvenile Dermatomyositis: Understanding This Rare Autoimmune Skin and Muscle Condition"},"content":{"rendered":"\n

Juvenile dermatomyositis is a rare autoimmune condition that can affect your child\u2019s skin, muscles, and sometimes other parts of the body. The early signs are not always easy to recognise, and symptoms such as tiredness, difficulty climbing stairs, or an unusual rash can initially be mistaken for a minor illness or another childhood skin condition.<\/p>\n\n\n\n

The name describes the two main parts of the body involved. “Dermato” refers to the skin, while “myositis” means inflammation of the muscles. Although the condition is uncommon, it can affect your child’s strength, mobility and everyday activities, particularly when inflammation is not brought under control.<\/p>\n\n\n\n

Learning that your child may have an autoimmune condition can feel overwhelming. Treatments are available to control inflammation, improve muscle strength and reduce the risk of long-term complications. Many children achieve good disease control, particularly when treatment begins promptly, although some experience relapses or require longer-term treatment and monitoring.<\/p>\n\n\n\n

Early assessment by a specialist paediatric team is particularly important. Because juvenile dermatomyositis can affect the skin, muscles, blood vessels and other organs, care commonly involves paediatric rheumatology working alongside dermatology, physiotherapy and other specialists when needed. Prompt recognition and treatment may help control inflammation, protect physical function and reduce the risk of long-term complications.<\/p>\n\n\n\n

What Is Juvenile Dermatomyositis?<\/strong><\/h2>\n\n\n\n

Juvenile dermatomyositis (JDM) is a rare autoimmune inflammatory condition that develops during childhood. If your child has JDM, their immune system mistakenly attacks healthy tissues, causing inflammation that mainly affects the skin and muscles. This can lead to characteristic skin rashes and muscle weakness.<\/p>\n\n\n\n

Your child’s immune system is designed to protect them from infections, but in JDM it becomes overactive and targets the body’s own tissues instead. Without treatment, this inflammation can affect the small blood vessels, muscles, and skin, which is why an early diagnosis and specialist care are so important.<\/p>\n\n\n\n

The severity of JDM varies from one child to another. Your child may develop relatively mild symptoms, while others need more intensive treatment and closer monitoring. It is important to remember that JDM is not contagious, so your child cannot pass it on to siblings, classmates, or anyone else.<\/p>\n\n\n\n

Why Does Juvenile Dermatomyositis Develop?<\/strong><\/h2>\n\n\n\n

The exact cause of juvenile dermatomyositis (JDM) is still not fully understood. Experts believe it develops through a combination of genetic susceptibility, changes in the immune system, and environmental factors that may trigger the condition in some children.<\/p>\n\n\n\n

Some children with juvenile dermatomyositis have a family history of autoimmune conditions such as type 1 diabetes, thyroid disease, inflammatory arthritis or lupus. However, JDM is not usually inherited in a simple or predictable way, and having an affected relative does not mean another child will develop the condition.<\/p>\n\n\n\n

Researchers continue to study whether viral infections, sunlight, or other environmental exposures can trigger JDM in susceptible children, but no single cause has been identified. It is important to remember that JDM is not caused by poor diet, everyday activities, or anything you did during pregnancy or your child’s early years.<\/p>\n\n\n\n

The Characteristic Skin Rash<\/strong><\/h2>\n\n\n\n

A distinctive skin rash is one of the main signs of juvenile dermatomyositis (JDM). In some children, you may notice the rash before any muscle weakness develops, while in others the skin and muscle symptoms appear at around the same time. The rash can look pink, red, violet, purple, brown, or darker than the surrounding skin, depending on your child’s natural skin tone.<\/p>\n\n\n\n

In children with darker skin tones, the rash may not appear obviously red, making it more difficult to recognise. You may instead notice changes in skin colour, texture, swelling, scaling, or tenderness. The rash is often sensitive to sunlight and may become more noticeable after sun exposure, although some children experience little discomfort.<\/p>\n\n\n\n

A skin rash on its own does not confirm juvenile dermatomyositis because several other skin conditions can look similar. Your child’s dermatologist will consider the appearance and location of the rash, together with muscle symptoms and other findings, to make an accurate diagnosis.<\/p>\n\n\n\n

Heliotrope Rash Around the Eyes<\/strong><\/h2>\n\n\n\n

A heliotrope rash is one of the characteristic skin changes seen in juvenile dermatomyositis. You may notice discolouration around your child’s upper eyelids, which can appear violet, purple, reddish-brown, or darker than the surrounding skin, depending on their natural skin tone. The eyelids may also look puffy or swollen.<\/p>\n\n\n\n

The name “heliotrope” comes from a purple-coloured flower, but the rash does not always appear bright purple. If your child has darker skin, you may notice subtle changes in pigmentation or swelling rather than an obvious violet colour. It is sometimes mistaken for tiredness, allergies, eczema, or irritation from rubbing the eyes.<\/p>\n\n\n\n

If your child has persistent eyelid discolouration or swelling together with muscle weakness, unusual tiredness, difficulty walking, or other skin rashes, you should seek medical advice. Your child’s specialist will assess these features alongside other signs of juvenile dermatomyositis to help make an accurate diagnosis.<\/p>\n\n\n\n

Gottron’s Papules and Gottron’s Sign<\/strong><\/h2>\n\n\n\n

Gottron’s papules are one of the characteristic skin features of juvenile dermatomyositis. You may notice raised, flat-topped papules or plaques over your child’s knuckles or finger joints. These areas can appear smooth, scaly, cracked, or thickened, and their colour may vary from red or violet to brown, purple-grey, or darker than the surrounding skin, depending on your child’s skin tone.<\/p>\n\n\n\n

Gottron’s sign refers to similar skin changes that develop over larger joints, particularly the elbows, knees, and sometimes the ankles. These rashes can easily be mistaken for eczema, psoriasis, warts, or irritation, but their location over the joints and their association with other symptoms can provide important clues.<\/p>\n\n\n\n

Your child may find these areas itchy, sore, or uncomfortable, especially if the skin becomes dry or cracked. If you notice persistent rashes over the knuckles or joints together with muscle weakness, unusual tiredness, or difficulty with everyday activities, it is important to seek a specialist assessment.<\/p>\n\n\n\n

Other Skin and Nailfold Changes<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Juvenile dermatomyositis can cause rashes on your child’s upper chest, shoulders, upper back, or neck. These patterns are sometimes called the V-sign or shawl-sign because of where the rash appears. You may also notice changes on the face, scalp, arms, thighs, hands, or other areas that are regularly exposed to sunlight.<\/p>\n\n\n\n

If your child’s scalp is affected, it may resemble eczema or psoriasis and can cause itching, scaling, or temporary hair shedding. Around the fingernails, you may notice redness, swelling, ragged cuticles, or tiny red spots. These nailfold changes are a common feature of JDM and can provide important clues about the condition.<\/p>\n\n\n\n

Your child’s specialist may examine the tiny blood vessels around the fingernails using a magnifying device or a specialised microscope. These changes can reflect ongoing inflammation, even when the skin rash appears to be improving, so they are assessed alongside your child’s other symptoms rather than as a separate nail problem.<\/p>\n\n\n\n

How Muscle Weakness Usually Appears<\/strong><\/h2>\n\n\n\n

The muscle weakness caused by juvenile dermatomyositis usually affects both sides of your child’s body. It most often involves the muscles closest to the body’s centre, including the shoulders, neck, hips, thighs, and upper arms. As a result, everyday movements that were once easy may gradually become more difficult.<\/p>\n\n\n\n

You may notice that your child struggles to climb stairs, get up from the floor, or stand from a low chair without using their hands for support. They may also find it harder to lift their arms to brush their hair, put on clothes, reach for objects, or carry a school bag that they previously managed without difficulty.<\/p>\n\n\n\n

The weakness often develops gradually, so it can sometimes be mistaken for tiredness, clumsiness, or a lack of fitness. Younger children may ask to be carried more often, avoid active play, or seem less willing to run and climb. If you notice a persistent decline in your child’s physical abilities, it is important to arrange a medical assessment.<\/p>\n\n\n\n

Swallowing, Breathing and Other Systemic Symptoms<\/strong><\/h2>\n\n\n\n

Juvenile dermatomyositis can sometimes affect the muscles used for swallowing. You may notice that your child coughs during meals, chokes on drinks, takes much longer to eat, or says that food feels as though it is getting stuck. Changes in their voice, such as sounding quieter, hoarse, or more nasal, may also occur.<\/p>\n\n\n\n

In some children, the condition can affect the muscles involved in breathing or cause inflammation in the lungs. If your child develops breathlessness, a persistent cough, chest discomfort or reduced exercise tolerance, it is important to seek medical advice promptly. Repeated chest infections may also require assessment, particularly if swallowing weakness is allowing food or drink to enter the airways.<\/p>\n\n\n\n

Your child’s specialist team may arrange baseline assessments for wider involvement, which can include pulmonary-function testing and, in some cases, ECG, echocardiography, swallowing assessment or imaging. The exact investigations and follow-up schedule will depend on your child’s age, symptoms, antibody profile, examination findings and specialist protocol.<\/p>\n\n\n\n

Juvenile Dermatomyositis Symptoms at a Glance<\/strong><\/h2>\n\n\n\n
Area Affected<\/strong><\/td>What You May Notice<\/strong><\/td>Why It Matters<\/strong><\/td><\/tr>
Skin<\/td>Rash around the eyelids, knuckles, elbows, knees, face, chest or upper back<\/td>Characteristic skin patterns may provide an early clue, even before weakness becomes obvious<\/td><\/tr>
Muscles<\/td>Difficulty climbing stairs, rising from the floor, lifting the arms or keeping up with play<\/td>These changes may indicate weakness in the muscles around the hips, shoulders and neck<\/td><\/tr>
Nailfolds<\/td>Redness, swelling, ragged cuticles or visible changes around the fingernails<\/td>Small blood-vessel changes can support the diagnosis and may reflect ongoing disease activity<\/td><\/tr>
Swallowing<\/td>Coughing, choking, taking longer to eat or a wet-sounding voice after drinking<\/td>Swallowing-muscle involvement requires prompt assessment because food or drink may enter the airway<\/td><\/tr>
Breathing or lungs<\/td>Breathlessness, persistent cough, chest discomfort or reduced exercise tolerance<\/td>These symptoms may require urgent investigation for respiratory muscle or lung involvement<\/td><\/tr>
Joints<\/td>Pain, stiffness or swelling<\/td>Joint inflammation can occur alongside skin and muscle symptoms<\/td><\/tr>
Soft tissues<\/td>Hard, sometimes painful lumps beneath the skin<\/td>These may represent calcinosis and should be assessed by the specialist team<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Symptoms That Require Urgent Medical Attention<\/strong><\/h2>\n\n\n\n

You should contact your child’s medical team urgently if their muscle weakness suddenly worsens or they begin struggling to walk, stand, lift their head, or use their arms as they normally would. A rapid change in strength may mean the condition has become more active and needs prompt assessment.<\/p>\n\n\n\n

Swallowing and breathing problems should never be ignored. If your child starts choking during meals, coughing when eating or drinking, has difficulty swallowing saliva, develops a wet-sounding voice after drinking, becomes breathless, or complains of chest pain, you should seek medical advice immediately. Call 999 if your child has severe breathing difficulty, blue or grey lips, collapses, becomes difficult to wake, or appears seriously unwell.<\/p>\n\n\n\n

You should also seek urgent medical review if your child develops severe abdominal pain, persistent vomiting, blood in their stools, black stools, painful skin ulcers, signs of skin infection, or becomes very unwell while taking medicines that suppress the immune system. Acting quickly when these symptoms develop can help your child receive the appropriate treatment without unnecessary delay.<\/p>\n\n\n\n

Can JDM Affect the Skin Without Obvious Weakness?<\/strong><\/h2>\n\n\n\n

Yes. A small number of children develop characteristic dermatomyositis skin changes without clinically apparent muscle weakness. These presentations may be described as part of the clinically amyopathic juvenile dermatomyositis spectrum.<\/p>\n\n\n\n

Amyopathic JDM means there is no obvious weakness or investigation evidence of muscle inflammation. In hypomyopathic JDM, there is no clinically apparent weakness, but blood tests, MRI or other investigations show subtle muscle involvement. Traditional definitions often use a six-month period, although treatment may sometimes begin earlier when clinically necessary.<\/p>\n\n\n\n

Even when your child appears to have normal strength, specialist follow-up remains important. Active skin and blood-vessel inflammation may still require treatment, and muscle involvement can sometimes develop later. A combined assessment involving paediatric rheumatology and dermatology can also help distinguish JDM from conditions such as lupus, eczema or psoriasis.<\/p>\n\n\n\n

How Juvenile Dermatomyositis Is Diagnosed<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

There is no single test that can confirm every case of juvenile dermatomyositis (JDM). Instead, your child’s specialist will consider the overall pattern of symptoms, including the skin rash, muscle weakness, physical examination findings, blood test results, and imaging studies. They will also ask when the symptoms first appeared and how your child’s strength and daily activities have changed over time.<\/p>\n\n\n\n

Your child’s muscle strength may be assessed through simple, age-appropriate tasks such as raising their arms, lifting their head, standing up from the floor, or climbing a step. The specialist will also examine the skin, scalp, fingernails, and the tiny blood vessels around the nailfolds, as these can provide important clues. Photographs showing how the rash has changed over time can also be helpful during the assessment.<\/p>\n\n\n\n

Because JDM can affect several parts of the body, your child will usually need assessment through a specialist paediatric rheumatology service, often working closely with dermatology, physiotherapy, occupational therapy and other teams. If your child has a persistent photosensitive rash together with muscle weakness or reduced physical function, prompt multidisciplinary assessment can help establish the diagnosis and begin appropriate treatment.<\/p>\n\n\n\n

\n

Blood Tests and Myositis Autoantibodies<\/strong><\/h2>\n\n\n\n

Blood tests are an important part of diagnosing juvenile dermatomyositis (JDM) and monitoring how active the condition is. Your child’s specialist may measure muscle-related enzymes and proteins such as creatine kinase (CK), aldolase and lactate dehydrogenase (LDH). Blood tests may also show raised transaminases, including AST and ALT, because these enzymes can be released from inflamed muscle as well as the liver. Your child’s clinical team will interpret the results together rather than assuming that an abnormal AST or ALT result represents liver disease.<\/p>\n\n\n\n

It is important to know that a normal creatine kinase level does not completely rule out JDM. Some children have only mildly raised muscle enzymes, while others may have normal results despite ongoing inflammation. Your child’s doctor may also arrange blood tests to assess blood counts, kidney and liver function, and general markers of inflammation before treatment begins.<\/p>\n\n\n\n

Your child may also have tests for myositis-specific and myositis-associated autoantibodies. These antibodies can help support the diagnosis and may provide clues about how the condition is likely to behave or whether certain complications are more likely. However, antibody results are only one part of the assessment, and your child’s specialist will always interpret them alongside the clinical examination, skin changes, muscle weakness, imaging, and other test results.<\/p>\n<\/div>\n\n\n\n

MRI Scans, Nailfold Examination and Biopsy<\/strong><\/h2>\n\n\n\n

An MRI scan is commonly used to look for muscle inflammation in children with juvenile dermatomyositis (JDM). It does not use radiation and can show which muscles are affected, helping your child’s specialist assess the extent of inflammation. In some cases, MRI can also help identify the best area to sample if a biopsy is needed. Younger children may need extra support to stay still during the scan, and sedation is occasionally considered.<\/p>\n\n\n\n

Your child’s specialist may also examine the tiny blood vessels around the fingernails using a technique called nailfold capillaroscopy. This painless test can reveal changes such as enlarged or reduced blood vessels and small areas of bleeding, which may provide useful information about disease activity. Electromyography (EMG), which measures the electrical activity of muscles, is used less often in children today because it can be uncomfortable and MRI usually provides the information needed without being invasive.<\/p>\n\n\n\n

A muscle or skin biopsy is not required for every child with JDM. However, if your child’s symptoms are unusual, test results do not clearly match the diagnosis, or another muscle condition needs to be ruled out, your specialist may recommend a biopsy. The decision is always based on your child’s individual situation and the information already gathered from the examination and other investigations.<\/p>\n\n\n\n

Treatment Goals and the Treat-to-Target Approach<\/strong><\/h2>\n\n\n\n

The main aim of treating juvenile dermatomyositis (JDM) is to control inflammation before it causes lasting damage to your child’s muscles, skin, or blood vessels. Treatment also aims to improve strength, restore everyday physical function, and reduce the risk of long-term complications.<\/p>\n\n\n\n

Specialists also focus on controlling ongoing skin inflammation, even if your child’s muscle strength is improving. Many now use a treat-to-target approach, setting clear treatment goals and reviewing progress regularly so that treatment can be adjusted if needed.<\/p>\n\n\n\n

Every child responds differently to treatment, so these goals are not a guarantee of how quickly the condition will improve. Your child’s treatment plan will be personalised according to their symptoms, test results, disease severity, response to medication, and overall wellbeing.<\/p>\n\n\n\n

Evidence Note<\/strong><\/p>\n\n\n\n

International treat-to-target recommendations published in 2025 identify inactive disease as the preferred treatment goal in juvenile dermatomyositis. This means aiming for no signs of active inflammatory disease in the muscles, skin or other affected organs rather than focusing only on improved strength or lower muscle-enzyme results.<\/p>\n\n\n\n

Minimal disease activity may be used as an alternative target when complete inactive disease cannot yet be achieved. Treatment goals should be agreed through shared decision-making with your child and family and reviewed regularly using symptoms, physical function, skin findings, blood tests and other appropriate assessments.<\/p>\n\n\n\n

These recommendations were developed using indirect evidence and international expert consensus because no clinical trial had directly compared a treat-to-target strategy with conventional non-targeted management in JDM.<\/p>\n\n\n\n

Corticosteroids and Methotrexate<\/strong><\/h2>\n\n\n\n

High-dose corticosteroids are usually the first medicines used to treat juvenile dermatomyositis (JDM) because they reduce inflammation quickly. Your child may take prednisolone by mouth or receive intravenous methylprednisolone if more intensive treatment is needed.<\/p>\n\n\n\n

Corticosteroids can cause side effects such as increased appetite, weight gain, mood changes, sleep problems, and a higher risk of infection. Your child’s specialist will gradually reduce the dose as the condition improves, and you should never stop steroid treatment suddenly unless you are specifically advised to do so.<\/p>\n\n\n\n

Methotrexate is commonly started alongside corticosteroids to help control muscle and skin inflammation while reducing the need for long-term high-dose steroids. Your child will need regular blood tests during treatment to monitor their blood-cell counts and liver function and to help ensure that the medicine remains safe.<\/p>\n\n\n\n

Specialist Guidance Note<\/strong><\/p>\n\n\n\n

International consensus recommendations advise that children with juvenile dermatomyositis should be managed by a specialist multidisciplinary paediatric team. Prompt recognition and treatment are important because prolonged active inflammation may be associated with muscle damage and other complications.<\/p>\n\n\n\n

For most children with active muscle inflammation, initial treatment generally includes high-dose corticosteroids together with methotrexate. The aim is to control inflammation promptly while limiting prolonged exposure to high-dose corticosteroids.<\/p>\n\n\n\n

Specialist teams should also assess for calcinosis, swallowing problems, wider organ involvement, functional difficulties and effects on quality of life. Treatments such as intravenous immunoglobulin, mycophenolate mofetil, rituximab or cyclophosphamide may be considered in severe, persistent or treatment-resistant disease.<\/p>\n\n\n\n

Additional Medicines for Persistent or Severe Disease<\/strong><\/h2>\n\n\n\n

Some children need additional medicines if juvenile dermatomyositis (JDM) remains active despite initial treatment. The choice of treatment depends on your child’s symptoms, disease severity, previous response to medication, and overall health.<\/p>\n\n\n\n

Depending on the pattern and severity of your child’s condition, the specialist team may consider treatments such as mycophenolate mofetil, ciclosporin, intravenous immunoglobulin (IVIG), rituximab or cyclophosphamide. Other immunomodulatory medicines may be used in selected cases, but treatment choices vary according to the organs affected, previous treatment response and the experience of the specialist centre.<\/p>\n\n\n\n

All immunosuppressive medicines require regular monitoring to ensure they are both safe and effective. Your child’s healthcare team will explain the possible side effects, arrange routine blood tests, and advise you about infection precautions, vaccinations, sun protection, and what to do if your child develops a fever or becomes unwell.<\/p>\n\n\n\n

Skin Care and Protection From Sunlight<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Sunlight can make the skin rash of juvenile dermatomyositis (JDM) worse and may contribute to increased disease activity in some children. You should use a high-factor, broad-spectrum sunscreen, encourage your child to wear protective clothing and a hat, and avoid prolonged exposure to strong midday sun whenever possible.<\/p>\n\n\n\n

Sun protection does not mean your child has to stay indoors. With sensible precautions, they can still enjoy outdoor activities, attend school, and take part in everyday life. Depending on your child’s age and the area affected, the specialist may prescribe a topical corticosteroid or a topical calcineurin inhibitor such as tacrolimus to help control active skin inflammation.<\/p>\n\n\n\n

Gentle emollients can help keep your child’s skin moisturised and reduce dryness or itching, but they do not replace anti-inflammatory treatment. If the rash spreads, becomes ulcerated, or does not improve despite following the treatment plan, you should contact your child’s clinical team for further advice.<\/p>\n\n\n\n

Physiotherapy, Exercise and Everyday Management<\/strong><\/h2>\n\n\n\n

While your child may need extra rest during periods of active inflammation, prolonged inactivity can lead to stiffness, reduced fitness, and further muscle weakness. As their condition improves, a specialist physiotherapist can develop a personalised exercise programme that helps rebuild strength, flexibility, and mobility safely.<\/p>\n\n\n\n

An occupational therapist may also support your child with everyday activities such as dressing, writing, bathing, and schoolwork. Temporary equipment or adjustments at school can help your child remain as independent as possible while they recover.<\/p>\n\n\n\n

Exercise is now recognised as an important part of managing juvenile dermatomyositis when it is carefully planned and monitored. Your child’s school may also need guidance about fatigue, sun protection, physical education, medication, and medical appointments so they can provide the right support during recovery.<\/p>\n\n\n\n

JDM can also affect confidence, friendships, school attendance and emotional wellbeing, particularly when a visible rash, fatigue, weakness or medication side effects make your child feel different from their peers. Your child’s team should ask how the condition is affecting daily life and arrange psychological, school or family support where needed.<\/p>\n\n\n\n

Clinical Tip<\/strong><\/p>\n\n\n\n

Keep a simple record of changes in your child’s strength, energy, swallowing, breathing and skin. Photographs taken in consistent lighting can help show whether a rash is spreading or improving, while notes about activities such as climbing stairs, rising from the floor, brushing hair or keeping up at school can help the clinical team monitor physical function.<\/p>\n\n\n\n

Do not increase, reduce or stop your child’s medicines or exercise programme without advice. During an active flare, the safest level of exercise should be agreed with the paediatric rheumatology and physiotherapy teams.<\/p>\n\n\n\n

Calcinosis, Long-Term Outlook and Latest Advances<\/strong><\/h2>\n\n\n\n

Calcinosis is a complication of juvenile dermatomyositis (JDM) in which calcium deposits form beneath your child’s skin or within muscles and other soft tissues. These deposits can feel like hard lumps, cause pain, restrict movement, or occasionally break through the skin. Early diagnosis and sustained control of inflammation may help reduce the risk of calcinosis, although calcium deposits can still develop despite appropriate treatment.<\/p>\n\n\n\n

The long-term outlook varies from one child to another. Some children achieve long-lasting remission after a single episode, while others experience relapses or need ongoing treatment and regular monitoring. Your child’s specialist will continue to assess their muscle strength, skin, growth, and overall health over time.<\/p>\n\n\n\n

Research into targeted treatments, including JAK inhibitors, is continuing for children with difficult-to-treat JDM. Most published experience involves children with persistent or refractory disease who have not responded adequately to established treatments, and the available evidence remains largely observational.<\/p>\n\n\n\n

JAK inhibitors are not routine first-line treatment for JDM, and they are not specifically licensed in the UK for this condition. Any off-label use would require careful consideration by a specialist paediatric rheumatology team, including discussion of uncertain benefits, infection risks, blood-test monitoring and other safety concerns.<\/p>\n\n\n\n

Research Insight<\/strong><\/p>\n\n\n\n

UK-led research published in 2025 identified mitochondrial abnormalities and interferon-related inflammatory changes in muscle tissue from children with untreated JDM. The initial spatial analysis involved muscle samples from three children with JDM and three controls, with selected findings subsequently assessed in additional samples and an independent dataset.<\/p>\n\n\n\n

The findings may help researchers understand why muscle function is impaired and could eventually support the development of new biomarkers or targeted treatments. However, this was an exploratory laboratory study involving small numbers of patients. Mitochondrial testing is not part of routine JDM care, and the research does not currently change established first-line treatment.<\/p>\n\n\n\n

Myth vs Fact<\/strong><\/h2>\n\n\n\n
Myth<\/td>Fact<\/td><\/tr>
Juvenile dermatomyositis is only a skin condition<\/td>JDM can affect the skin, muscles, small blood vessels and, less commonly, organs such as the lungs or digestive system<\/td><\/tr>
A normal creatine kinase result rules out JDM<\/td>Muscle enzymes can be normal or only mildly raised, so results must be considered alongside symptoms, examination and imaging<\/td><\/tr>
Children with JDM should avoid all physical activity<\/td>Carefully planned physiotherapy and exercise can help maintain movement, strength and fitness as inflammation comes under control<\/td><\/tr>
Sun protection is only needed to prevent sunburn<\/td>Ultraviolet exposure can worsen the characteristic rash and may contribute to increased disease activity in some children<\/td><\/tr>
Medicines can be stopped as soon as strength improves<\/td>Skin or blood-vessel inflammation may remain active even when strength improves, so medicines must only be reduced under specialist supervision<\/td><\/tr>
Juvenile dermatomyositis carries the same cancer association as adult dermatomyositis<\/td>Unlike adult dermatomyositis, childhood JDM is not generally associated with an increased underlying cancer risk<\/td><\/tr>
JAK inhibitors are standard first-line treatment for JDM<\/td>They remain emerging specialist options mainly reported in treatment-resistant disease and are not routine first-line therapy<\/td><\/tr>
Calcinosis is simply a cosmetic problem<\/td>Calcium deposits can cause pain, restrict movement, ulcerate or become infected and therefore require specialist assessment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n